VSCA Stock Overview
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs in Germany.
Price History & Performance
|Historical stock prices|
|Current Share Price||€1.99|
|52 Week High||€7.90|
|52 Week Low||€1.88|
|1 Month Change||0.50%|
|3 Month Change||-15.14%|
|1 Year Change||-72.36%|
|3 Year Change||-86.08%|
|5 Year Change||-88.63%|
|Change since IPO||-98.20%|
Recent News & Updates
We're Not Very Worried About 4SC's (ETR:VSCA) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
We Think 4SC (ETR:VSCA) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
|VSCA||DE Biotechs||DE Market|
Return vs Industry: VSCA underperformed the German Biotechs industry which returned -31.4% over the past year.
Return vs Market: VSCA underperformed the German Market which returned -12.9% over the past year.
|VSCA Average Weekly Movement||5.4%|
|Biotechs Industry Average Movement||8.0%|
|Market Average Movement||6.3%|
|10% most volatile stocks in DE Market||10.6%|
|10% least volatile stocks in DE Market||3.5%|
Stable Share Price: VSCA is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: VSCA's weekly volatility (5%) has been stable over the past year.
About the Company
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs in Germany. Its products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase Ib/II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. The company also out-licenses its products to pharma and biotech companies for the treatment of cancer.
4SC Fundamentals Summary
|VSCA fundamental statistics|
Is VSCA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VSCA income statement (TTM)|
|Cost of Revenue||€392.00k|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 09, 2022
|Earnings per share (EPS)||-1.01|
|Net Profit Margin||-72.56%|
How did VSCA perform over the long term?See historical performance and comparison
Is 4SC undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate VSCA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate VSCA's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: VSCA is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: VSCA is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VSCA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VSCA is good value based on its PB Ratio (0.7x) compared to the DE Biotechs industry average (1.5x).
How is 4SC forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as 4SC has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has 4SC performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VSCA is currently unprofitable.
Growing Profit Margin: VSCA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VSCA is unprofitable, and losses have increased over the past 5 years at a rate of 1.7% per year.
Accelerating Growth: Unable to compare VSCA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VSCA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: VSCA has a negative Return on Equity (-36.75%), as it is currently unprofitable.
How is 4SC's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: VSCA's short term assets (€29.5M) exceed its short term liabilities (€5.4M).
Long Term Liabilities: VSCA's short term assets (€29.5M) exceed its long term liabilities (€1.1M).
Debt to Equity History and Analysis
Debt Level: VSCA is debt free.
Reducing Debt: VSCA had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VSCA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VSCA has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 5.2% each year.
What is 4SC current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VSCA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VSCA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VSCA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VSCA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as VSCA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Jason Loveridge, B.Sc, Ph D, FRSM, has been Corporate Advisor of Resonance Health Limited since June 30, 2017. Dr. Loveridge is a Founder of Invex.Dr. Loveridge has been Chairman of Management Board a...
CEO Compensation Analysis
Compensation vs Market: Jason's total compensation ($USD547.53K) is above average for companies of similar size in the German market ($USD404.30K).
Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.
Experienced Board: VSCA's board of directors are seasoned and experienced ( 11.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
4SC AG's employee growth, exchange listings and data sources
- Name: 4SC AG
- Ticker: VSCA
- Exchange: XTRA
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €20.127m
- Shares outstanding: 10.11m
- Website: https://www.4sc.com
Number of Employees
- 4SC AG
- Fraunhoferstrasse 22
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.